Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance.

MLA

Yamamura, Takashi, et al. “Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-Month Interim Analysis of Post-Marketing Surveillance.” Neurology & Therapy, vol. 13, no. 5, Oct. 2024, pp. 1361–83. EBSCOhost, https://doi.org/10.1007/s40120-024-00640-7.

APA

Yamamura, T., Isobe, N., Kawachi, I., Nohara, C., Miyazaki, Y., Tomita, M., Tsumuraya, T., Yamashita, K., Nakahara, J., Nakashima, I., & Fujihara, K. (2024). Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance. Neurology & Therapy, 13(5), 1361–1383. https://doi.org/10.1007/s40120-024-00640-7

Chicago

Yamamura, Takashi, Noriko Isobe, Izumi Kawachi, Chiyoko Nohara, Yusei Miyazaki, Minami Tomita, Takahiko Tsumuraya, et al. 2024. “Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-Month Interim Analysis of Post-Marketing Surveillance.” Neurology & Therapy 13 (5): 1361–83. doi:10.1007/s40120-024-00640-7.